Monitoring CgA and vasostatin‐1 levels in cancer patients before and after doxorubicin therapy, the administration of low‐dose full‐length CgA to patients with low CgA levels might represent a novel approach to prevent doxorubicin‐induced cardiotoxicity, thereby meriting further investigation. This evidence concerns the gene CGA and cancer.